2. Signaling Pathways
  3. GPCR/G Protein
  4. GLP Receptor

GLP Receptor

GLP Receptor

The GLP receptors contain two family members, GLP-1 receptor (GLP1R, or GLP-1R) and GLP-2 receptor (GLP2R or GLP-1R), activated by the glucagon-like peptides (GLPs). GLPs are s secreted by intestinal cells; causes insulin release; inhibits glucagon secretion, appetite, and energy intake; and delays gastric emptying because GLP receptors are located on the gut, pancreas, brainstem, hypothalamus, and vagal-afferent nerves. GLP-1 has only one known receptor, GLP1R, and regulates gut motility, appetite, islet function, and glucose homeostasis, whereas GLP-2, the agonist of GLP2R, enhances intestinal nutrient absorption. GLP-1R agonists are used to treat diabetes and obesity, and a GLP-2R agonist is approved to treat short bowel syndrome. An investigation of the actions of GLP receptor activation on gallbladder motility has demonstrated that GLP-2 receptor activation increases gallbladder volume in vivo and decreases spontaneous activity in GBSM bundles ex vivo. Like the inhibitory transmitters, which elicit their actions via an adenylate cyclase-protein kinase A-KATP channel pathway, the GLP-2 receptor signals through this same pathway.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P990990
    Efsubaglutide alfa
    HY-P990990 is an GLP-1 receptor-targeting Fusion Protein.
    Efsubaglutide alfa
  • HY-145458A
    PF-06954522 citrate
    		Agonist
    PF-06954522 citrate is an orally active GLP-1R agonist. PF-06954522 citrate can be used for the study of type 2 diabetes mellitus.
    PF-06954522 citrate
  • HY-P1445
    HAEGTFTSDVSSYLE
    		98.16%
    HAEGTFTSDVSSYLE is a polypeptide from patent CN 102920658 B. GLP-I analog contains the sequence.
    HAEGTFTSDVSSYLE
  • HY-N2452
    Cochinchinenin C
    		Agonist
    Cochinchinenin C is a GLP-1R agonist that binds to the extracellular domain of the receptor via hydrophobic interactions and hydrogen bonds, and promotes glucose-dependent insulin secretion from pancreatic β-cells. Cochinchinenin C also increases intracellular cAMP and ATP levels. At low concentrations, Cochinchinenin C binds to human serum albumin, alters its microenvironment, and induces dominant static fluorescence quenching. Cochinchinenin C shows almost no cytotoxicity to pancreatic β-cells, and exerts a synergistic effect with Loureirin A (HY-N1505) when binding to human serum albumin. Cochinchinenin C has been widely used in studies of type 2 diabetes, Helicobacter pylori infection, thrombotic diseases, and other conditions.
    Cochinchinenin C
  • HY-178767
    ECC-5004
    		Agonist
    ECC-5004 (Compound 1) is a GLP-1 receptor agonist with an EC50 of 0-20 nM. ECC-5004 exhibits strong inhibitory effects on OATP1B1, with an IC50 < 1 μM. ECC-5004 can be used to study diseases such as diabetes, obesity, and non-alcoholic fatty liver disease.
    ECC-5004
  • HY-P11674
    Zantrutide
    		Agonist
    Zantrutide is a glucagon, gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Zantrutide can be used for the study of metabolic diseases.
    Zantrutide
  • HY-183694
    GLP-1 receptor agonist 22
    		Agonist
    GLP-1 receptor agonist 22 is an orally active GLP-1 receptor agonist. GLP-1 receptor agonist 22 promotes the accumulation of cAMP. GLP-1 receptor agonist 22 reduces blood glucose levels and inhibits feeding behavior in human glucagon-like peptide-1 receptor knock-in mice. GLP-1 receptor agonist 22 can be used in the research of type 2 diabetes and obesity.
    GLP-1 receptor agonist 22
  • HY-P5161
    FC382K10W15
    		Agonist
    FC382K10W15 is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 can be used in type 2 diabetes research.
    FC382K10W15
  • HY-P11270
    Relsipatide
    		Agonist
    Relsipatide (BG128) is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research.
    Relsipatide
  • HY-P10318
    SHR-2042
    		Antagonist
    SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency.
    SHR-2042
  • HY-143312C
    (S)-V-0219
    		Modulator
    (S)-V-0219 is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (S)-V-0219 activates calcium fluxes in HEK cells stably expressing hGLP-1R. (S)-V-0219 is orally active and ameliorates high glucose levels in mice and inhibits feeding behavior in fasted mice.
    (S)-V-0219
  • HY-162306
    GLP-1R agonist 18
    		Agonist
    GLP-1R agonist 18 (example 117) is an agonist for GLP-1R with an EC50 of 0.044 nM.
    GLP-1R agonist 18
  • HY-P3389
    Vurolenatide
    Vurolenatide is a long-lasting GLP-1 analogue. Vurolenatide can be studied in research on short bowel syndrome.
    Vurolenatide
  • HY-P992407
    MEDI-4166
    MEDI-4166 is an antibody-peptide gene fusion molecule of a PCSK9 antibody and a GLP-1 analog. MEDI-4166 is applicable to research related to type 2 diabetes.
    MEDI-4166
  • HY-147628
    GLP-1R agonist 15
    		Agonist
    GLP-1R agonist 15 (Compound 101) is a GLP-1 receptor agonist.
    GLP-1R agonist 15
  • HY-162436
    GLP-1R agonist 21
    		Agonist
    GLP-1R agonist 21 (Compound I-134) is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC50 of 0.0104 nM.
    GLP-1R agonist 21
  • HY-P5161A
    FC382K10W15 TFA
    		Agonist
    FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research.
    FC382K10W15 TFA
  • HY-P11670
    Linvixdutide
    		Agonist
    Linvixdutide is a glucagon and glucagon-like peptide 1 receptor (GLP-1R) agonist with anti-obesity effects.
    Linvixdutide
  • HY-P11043
    GEP44
    		Agonist
    GEP44 is a peptide biased triple agonist targeting Glucagon-like peptide 1 receptor (GLP-1R), neuropeptide Y1 Receptor (Y1-R), and neuropeptide Y2 Receptor (Y2-R). GEP44 induces Y1-R antagonist-controlled, GLP-1R-dependent stimulation of insulin secretion in both rat and human pancreatic islets by counteracting effects of Y1-R and GLP-1R agonism. GEP44 promotes insulin-independent Y1-R-mediated glucose uptake in muscle tissue and significantly reduces food intake and body weight in diet-induced obese rat models. GEP44 can be used for obesity and type 2 diabetes mellitus research.
    GEP44
  • HY-170511
    GLP-1 receptor agonist 15
    		Agonist
    GLP-1 receptor agonist 15 (Example 4) is a GLP receptor agonist with an EC50 of 0.74 nM. The IC50 for the hERG potassium ion channel is 10.1 μM. GLP-1 receptor agonist 15 can be used for research in the field of diabetes.
    GLP-1 receptor agonist 15
Cat. No. Product Name / Synonyms Application Reactivity